Evidence map›Paper›PMID 26828056›Full record

ArticleThe European respiratory journal2016

End TB with precision treatment!

Evelien P M van der Burgt, Marieke G G Sturkenboom, Mathieu S Bolhuis, Onno W Akkerman, Jos G W Kosterink, Wiel C M de Lange, Frank G J Cobelens, Tjip S van der Werf, Jan-Willem C Alffenaar

Registry-linked trialAbstract readLetterComment
PubMed Publisher
In one paragraph

Article in The European respiratory journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02816931 (Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study), which is not on this map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02816931 completednot on this map

Plasma Drug Concentrations in the Treatment of Multidrug-resistant Tuberculosis in Relation to Minimum Inhibitory Concentrations - a Prospective Observational Study

TypeobservationalSponsorKarolinska InstitutetRan2016 to 2020Enrolled37ConditionsTuberculosis, Multidrug Resistant
3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Therapeutic drug monitoring in tuberculosis.European journal of clinical pharmacology · 2024
    Review
  4. Article
  5. Article
  6. Clinical standards for drug-susceptible pulmonary TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Integrating Pharmacokinetics and Pharmacodynamics in Operational Research to End Tuberculosis.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020
    Article
  14. Article
  15. Observational
  16. Article
  17. Review
  18. Therapeutic Drug Monitoring in Tuberculosis: Practical Application for Physicians.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors.

Evelien P M van der BurgtUniversity of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Marieke G G SturkenboomUniversity of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Mathieu S BolhuisUniversity of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Onno W AkkermanUniversity of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
Jos G W KosterinkUniversity of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands.
Wiel C M de LangeUniversity of Groningen, University Medical Center Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands University of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands.
Frank G J CobelensKNCV Tuberculosis Foundation, The Hague, The Netherlands Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.
Tjip S van der WerfUniversity of Groningen, University Medical Center Groningen, Tuberculosis Center Beatrixoord, Haren, The Netherlands University of Groningen, University Medical Center Groningen, Dept of Internal Medicine, Groningen, The Netherlands.
Jan-Willem C AlffenaarUniversity of Groningen, University Medical Center Groningen, Dept of Clinical Pharmacy and Pharmacology, Groningen, The Netherlands j.w.c.alffenaar@umcg.nl.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Developed CountriesGlobal HealthAntitubercular AgentsCommunicable Disease ControlFemaleHumansMaleTuberculosisAntitubercular Agents

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.